We are a biopharmaceutical company focused on leveraging our proprietary ImmunoTAC™ technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Our ImmunoTAC™ platform is the result of a focused effort to discover ways to systemically deliver disease-modifying small molecules in a directed fashion to sites of disease. Our platform enables us to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Many potentially promising systemic therapies fail to maximize their therapeutic potential due to toxicities in healthy tissues. Our approach is designed to expand the therapeutic window and avert unacceptable toxicities by directly targeting specific disease sites where our therapeutics are locally active.
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
Data Provided by Refinitiv. Minimum 15 minutes delayed.
07-21-2022 2:00 PM PDT
05-24-2022 7:00 AM EDT
03-31-2022 2:00 PM PDT